Live Market Updates
Latest Financial News
News Feed
1 articles
Personalized
Live Market Updates
Latest Financial News
neutral-positive
3 days agoNovartis shares slip while Avidity soars after US$12 billion biotech deal
Swiss pharmaceutical giant Novartis announced it will acquire US biotech firm Avidity Biosciences in a deal valued around US$12 billion, the largest take-over under CEO Vas Narasimhan. Following the announcement, Novartis shares declined ~1% while Avidity’s stock surged. Market watchers view the deal as strategic for Novartis’s RNA-based therapies pipeline, even as price tag and integration risks weigh on the acquirer. The transaction underscores high valuations in biotech innovation and continuing consolidation trends in the sector.
neutral-positive
3 days agoNovartis shares slip while Avidity soars after US$12 billion biotech deal
Swiss pharmaceutical giant Novartis announced it will acquire US biotech firm Avidity Biosciences in a deal valued around US$12 billion, the largest take-over under CEO Vas Narasimhan. Following the announcement, Novartis shares declined ~1% while Avidity’s stock surged. Market watchers view the deal as strategic for Novartis’s RNA-based therapies pipeline, even as price tag and integration risks weigh on the acquirer. The transaction underscores high valuations in biotech innovation and continuing consolidation trends in the sector.
neutral-positive
Novartis shares slip while Avidity soars after US$12 billion biotech deal
3 days ago
1 min read
76 words
Novartis to acquire Avidity Biosciences for ~US$12 billion; acquirer’s shares dip while target’s soar.
Swiss pharmaceutical giant Novartis announced it will acquire US biotech firm Avidity Biosciences in a deal valued around US$12 billion, the largest take-over under CEO Vas Narasimhan. Following the announcement, Novartis shares declined ~1% while Avidity’s stock surged. Market watchers view the deal as strategic for Novartis’s RNA-based therapies pipeline, even as price tag and integration risks weigh on the acquirer. The transaction underscores high valuations in biotech innovation and continuing consolidation trends in the sector.
Swiss pharmaceutical giant Novartis announced it will acquire US biotech firm Avidity Biosciences in a deal valued around US$12 billion, the largest take-over under CEO Vas Narasimhan. Following the announcement, Novartis shares declined ~1% while Avidity’s stock surged. Market watchers view the deal as strategic for Novartis’s RNA-based therapies pipeline, even as price tag and integration risks weigh on the acquirer. The transaction underscores high valuations in biotech innovation and continuing consolidation trends in the sector.
Tags:
stocks
global
stocks
global
healthcare
mergers & acquisitions
biotech
Oct 27, 2025 • 20:29 IST